These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36111954)

  • 1. Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database.
    Ma Z; Zhang Y; Zhu M; Feng L; Zhang Y; An Z
    Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1351-1361. PubMed ID: 36111954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
    Hackshaw MD; Danysh HE; Singh J; Ritchey ME; Ladner A; Taitt C; Camidge DR; Iwata H; Powell CA
    Breast Cancer Res Treat; 2020 Aug; 183(1):23-39. PubMed ID: 32591987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
    N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China.
    Xu C; Chen Z; Xia Y; Shi Y; Fu P; Chen Y; Wang X; Zhang L; Li H; Chen W; Fu J; Huang L; Shu J; Wang O; Wu W; Xie B; Wang T; Zhang W; Shen S; Li Q; Luo T; Zhang B; Xie Y; Wang H; Wang Q; Wang W; Li Z; Song Z; Fang W; Zhong W; Zhang Y; Zhan P; Liu H; Lv T; Miao L; Min L; Wang F; Meng R; Zhu Y; Wang L; Wan B; Wang D; Hao Y; Zhou J; Huang L; Zhang Z; Lv D; Fang M; Lu Y; Si L; Song Y; Wang X
    Cancer; 2024 Sep; 130(S17):3054-3066. PubMed ID: 39092590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung toxicity induced by anti-HER2 antibody - drug conjugates for breast cancer.
    Chai M; Li L; Wu H; Liu Y; Yi Z; Yu H
    Crit Rev Oncol Hematol; 2024 Mar; 195():104274. PubMed ID: 38295890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database.
    Ma P; Tian H; Shi Q; Liu R; Zhang Y; Qi X; Chen Y
    Expert Opin Drug Saf; 2023; 22(8):685-696. PubMed ID: 37068935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
    N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
    Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
    Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
    Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
    Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.
    Tarantino P; Modi S; Tolaney SM; Cortés J; Hamilton EP; Kim SB; Toi M; Andrè F; Curigliano G
    JAMA Oncol; 2021 Dec; 7(12):1873-1881. PubMed ID: 34647966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
    Nie T; Blair HA
    Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
    Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
    JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Yamaguchi K;
    N Engl J Med; 2020 Jun; 382(25):2419-2430. PubMed ID: 32469182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
    Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
    J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
    Powell CA; Modi S; Iwata H; Takahashi S; Smit EF; Siena S; Chang DY; Macpherson E; Qin A; Singh J; Taitt C; Shire N; Camidge DR
    ESMO Open; 2022 Aug; 7(4):100554. PubMed ID: 35963179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis - A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up.
    Chang CH; Jung CJ; Huang YM; Chiao L; Chang YL; Hsieh SC; Lin CH; Kuo YM
    Breast; 2022 Feb; 61():35-42. PubMed ID: 34894465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.